Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies

Janssen, Biogen And Astellas Execs Discuss Portfolio Priorities

Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.

Cell and gene therapies often originate at small biopharmaceutical firms, but big pharma and large biotech companies continue to increase their investments in these new modalities when they see external innovations that fit within their research and development strategies. Therapeutic area priorities and unmet needs drive these business development decisions, according to executives from Janssen, Biogen, Inc. and Astellas Pharma, Inc.

Sanjaya Singh, vice president and global head at Janssen BioTherapeutics and Janssen Research & Development LLC (subsidiaries of Johnson...